Issue Date: June 19, 2017
Celgene in cancer deal with Dragonfly
Celgene will pay Dragonfly Therapeutics $33 million up front as part of an immuno-oncology drug development pact. Celgene gains the right to license up to four blood cancer treatments developed using Dragonfly’s technology platform. Launched in 2015, Dragonfly is developing therapies that can link proteins expressed on the surface of cancer cells to white blood cells called natural killer cells, which then alert other immune cells to attack the cancer cells.
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society